losartan / Generic mfg. - LARVOL DELTA

Bu Shen Huo Xue Formula ameliorates chronic kidney disease and suppresses NLRP3 inflammasome-mediated pyroptosis and renal fibrosis. (PubMed, Pathol Res Pract) - "BSHX ameliorated renal dysfunction and injury in CKD mice and was associated with suppression of NLRP3 inflammasome-mediated pyroptosis, inflammation, and fibrosis. Under the present experimental conditions, BSHX did not induce detectable abnormalities in the evaluated serum indices of hepatic or renal function."

Journal • Cardiovascular • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • Reperfusion Injury • IL18 • IL1B • IL6 • MMP9 • NLRP3 • TNFA

Risks of Infections among New Users of Losartan vs. Amlodipine in Patients with Musculoskeletal Conditions: A Real-World Study of Medicare Beneficiaries (ACR Convergence 2026) - No abstract available

Clinical • Medicare • Real-world • Real-world evidence • Reimbursement • US reimbursement • Infectious Disease • Musculoskeletal Diseases

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - P2 | N=27 | Not yet recruiting | Sponsor: Massachusetts General Hospital | Initiation date: Aug 2026 ➔ Feb 2027

Platinum resistant • Trial initiation date • Oncology • Ovarian Cancer • Solid Tumor

A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). (ASCO 2026) - P2 | "Although clinical outcomes with the novel combinations did not exceed historical standards of care, this non-comparator phase II study demonstrates the feasibility and tolerability of combinatorial pathway inhibition in mPDAC. This study enables ongoing correlative analyses of EMT plasticity, stromal remodeling, and immune escape in mPDAC and establishes a robust platform to define determinants of resistance and durable response."

Clinical • Metastases • P2 data • Fibrosis • Infectious Disease • Oncology • Pancreatic Ductal Adenocarcinoma • Septic Shock • TGFB1

Collateral Damage: IgA Nephropathy Complicating Long-Term Certolizumab Pegol Use in Crohn's Disease (ACG 2026) - "Case Description/ A 36-year-old male with CD diagnosed in 2010 (Paris classification: A2, L1, B2), underwent ileocolonic resection and was started on certolizumab pegol in 2011 after failing 5-aminosalicylic acid, 6-mercaptopurine, and infliximab therapy...Certolizumab pegol was stopped and CD treatment with vedolizumab was started. Treatment with corticosteroids, mycophenolate, losartan, and atrasentan was initiated...Targeted budesonide was not a treatment option in this case given prior bowel resection, which emphasizes a treatment consideration unique to CD patients. This case emphasizes the importance of routine renal monitoring in patients on long-term anti-TNF therapy. Figure: Light microscopy (PAS stain) demonstrating mesangial hypercellularity Figure: Immunofluorescence microscopy demonstrating diffuse mesangial IgA deposits"

Crohn's disease • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammation • Inflammatory Bowel Disease • Nephrology • Renal Disease

Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report. (PubMed, CEN Case Rep) - "Notably, his proteinuria improved following discontinuation of durvalumab and treatment with losartan potassium, dapagliflozin, and finerenone, without a substantial increase in the glucocorticoid dose. The clinical course highlights the heterogeneity of durvalumab-associated nephrotic syndrome."

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Infectious Disease • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Solid Tumor

Therapeutic Targeting of Epithelial Mesenchymal Cellular Plasticity in Pancreatic Cancer. (PubMed, Clin Cancer Res) - P2 | "GSK-3b blockade synergizes with FFX by modulating PDAC plasticity while promoting the development of a tumor suppressive immune microenvironment."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • CD8 • CEACAM6 • FN1 • TGFB1

The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. (PubMed, Pharmacotherapy) - P2 | "Daily losartan reduced and delayed clinically significant paclitaxel-induced neuropathy while improving patient-reported outcomes, without additional toxicity. These findings support repurposing losartan as a low-cost PIPN prophylactic and justify validation in larger, multicenter trials."

Clinical • Journal • Breast Cancer • Gynecologic Cancers • Oncology • Pain • Peripheral Neuropathic Pain • Solid Tumor • NGF

Losartan's regulation of PI3K/AKT signaling underlies its combined anti-seizure and antidepressant effects in epileptic rats. (PubMed, Epilepsy Res) - "Losartan may attenuate both seizures and depression-like behaviors in epileptic rats by activating the hippocampal PI3K/AKT signaling pathway and inhibiting neuronal apoptosis. These results highlight its potential as an adjunctive therapy for epilepsy with comorbid depression."

IO biomarker • Journal • Preclinical • CNS Disorders • Depression • Epilepsy • Psychiatry • BCL2 • CASP3

The GranStone Trial (clinicaltrials.gov) - P2/3 | N=100 | Not yet recruiting | Sponsor: Martin Blomberg Jensen

New P2/3 trial • Nephrology • Renal Calculi

Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies. (PubMed, Cardiovasc Drugs Ther) - "Allopurinol is a widely used compound in medical practice for gout, and has been proven safe, economical and effective in other cardiovascular diseases. The recent approval of allopurinol as an orphan drug for the treatment of MFS by the European Medicines Agency (EMA) adds further value to its potential inclusion in standard medical therapy in the near future."

Journal • Review • Cardiovascular • Genetic Disorders • Gout • Inflammatory Arthritis • Rheumatology • FBN1

Impact of Losartan Nanoparticles on Carbon Tetrachloride-induced Cerebellar Injury in Rats: Association with Alterations in RIPK1/RIPK3/MLKL Necroptosis Markers. (PubMed, Mol Neurobiol) - "These findings highlighted LP-NPs as a prospective biochemical, molecular, and histological protective agent against CCL₄-induced cerebellar injury. Further studies are required to confirm the direct involvement of the RIPK1/RIPK3/MLKL necroptosis pathway."

Biomarker • Journal • Preclinical • CNS Disorders • Oncology • CASP8 • CAT • GFAP • RIPK1 • TNFA

Donor APOL1 high-risk genotypes and early graft failure: Two cases of De Novo collapsing FSGS with second hits (TTS 2026) - "Her post-transplant course was complicated by antibody-mediated rejection (ABMR) at 1 month requiring plasmapheresis/IVIG/eculizumab, followed by mixed AMR/ACR at 4 months...Despite treatment with losartan and resolution of DSAs, she experienced progressive graft dysfunction with creatinine rising to 4.09 mg/dL by 11 months post-transplant, with ongoing nephrotic range proteinuria...Despite plasmapheresis, RAAS inhibition, SGLT2 inhibition, and sparsentan, his creatinine rose to 5.74 mg/dL with protein/creatinine ratio of 12.44 g/g by 10 months, necessitating dialysis initiation... Both cases illustrate the "two-hit" hypothesis of APOL1-mediated kidney disease, where donor high-risk genotypes combined with immunologic injury (rejection) and/or viral infections (BK, CMV) precipitate rapid cFSGS development and graft failure within the first year. These cases underscore the importance of donor APOL1 genotyping and heightened surveillance for rejection and viral..."

Clinical • Antibody-mediated Rejection • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Transplant Rejection • Type 2 Diabetes Mellitus

COMPARATIVE EFFECTIVENESS OF LOSARTAN VERSUS BETA-BLOCKERS FOR PREVENTING AORTIC ANEURYSM GROWTH IN MARFAN SYNDROME: AN UMBRELLA REVIEW OF META-ANALYSES (CHEST 2026) - No abstract available

HEOR • Review • Cardiovascular • Genetic Disorders

Acute effects of AT1 receptor blockade on approach-avoidance of negative emotional faces. (PubMed, Neuropsychopharmacology) - P1 | "We sought to examine the impact of acute losartan, an angiotensin type 1 (AT1) receptor blocker, on the implicit approach-avoidance of facial expressions and checkerboard controls in healthy adults...The response pattern associated with AT1 receptor blockade may counteract previously observed depressive tendencies, suggesting effects possibly consistent with antidepressant treatments. Our findings further highlight the RAS as a mechanistically relevant target for psychiatry, suggesting that AT1 receptor antagonism may have relevance for treating depression and other emotional disorders characterized by aberrant motivational biases (Clincialtrials.gov ID: NCT06624904)."

Journal • CNS Disorders • Depression • Psychiatry

Effects of Kudzu Root (Gegen) on Drug-Metabolizing Enzymes and Blood Clotting in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Chinese University of Hong Kong

Biomarker • New P1 trial • Thrombosis • CYP2C19 • CYP2C9 • CYP3A4

Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus. (PubMed, J Hum Hypertens) - "Secondary analyses were also not significantly different. Overall, this study did not detect sufficient evidence that telmisartan reduces NODM risk compared with losartan, valsartan, or candesartan."

Journal • Diabetes • Metabolic Disorders • PPARG

Effects of Losartan, Empagliflozin, and Their Combination on Uric Acid Concentrations in People With Type 2 Diabetes. (PubMed, Kidney Med) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Hierarchically porous hyper-crosslinked polymer-coated SPME fibers for enrichment and sensitive detection of N-nitrosamine genotoxic impurities in pharmaceutical products. (PubMed, J Chromatogr A) - "The practical applicability of the method was further validated through the successful determination of N-nitrosamine impurities in nine commercially available losartan potassium tablet products. The proposed HCP-SPME-GC-MS strategy provides a cost-effective, sensitive, and robust approach for the monitoring of trace nitrosamine genotoxic impurities in pharmaceutical products."

Journal

Losartan inhibits methotrexate-induced testicular damage via anti-inflammatory and anti-apoptotic effects. (PubMed, Immunopharmacol Immunotoxicol) - "Our data collectively demonstrate that AT1R inhibition using Losartan successfully mitigates MTX-induced testicular damage by addressing this upstream mechanistic pathway. Losartan has been identified as a viable treatment strategy for preserving male reproductive function following cytotoxic therapy."

Journal • Inflammation • CASP3 • TNFA

AT1R-mediated NIR-II/PA imaging-guided iCM exosome therapy for myocardial ischemia revascularization. (PubMed, Sci Adv) - "The system is coloaded with losartan and exosomes derived from induced pluripotent stem cell-derived cardiomyocytes (iCMs), enabling noninvasive, high-resolution visualization and evaluation of myocardial injury...The synergistic therapeutic efficacy of this system was systematically validated in established mouse and rat models of MI/RI, demonstrating enhanced angiogenesis, attenuation of fibrosis, and improved cardiac functional recovery. Collectively, this study establishes a multifunctional platform that integrates diagnosis and therapy, providing a promising strategy for the precise management of MI/RI."

Journal • Cardiovascular • Coronary Artery Disease • Fibrosis • Heart Failure • Immunology • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury

Inflammation of the calcified aortic valve in cardiac patients is associated with activation of the local aldosterone system, promoting oxidative stress–driven pathological responses (ESC 2026) - "In PBMCs, glucose uptake was quantified using 2-NBDG, and aldosterone release by ELISA. ROS levels were increased 1.7-fold in calcified aortic valve regions compared with non-calcified areas, and this augmented oxidative activity was significantly attenuated by NAC, losartan, VAS-2870, empagliflozin, eplerenone, and FAD286. Aldosterone synthase is upregulated in calcified aortic valves, particularly within infiltrating macrophages, and promotes pro-oxidant and metabolic dysregulation in both valve tissue and PBMCs. These findings suggest that aldosterone signaling contributes to the progression of calcified aortic stenosis and represents a potential therapeutic target."

Clinical • Oxidative stress • Cardiovascular • Heart Failure • CD68

Potentiated angiotensin AT1 receptor activity is associated with age-dependent expansion of adrenal-projecting presympathetic circuitry in hypertension. (PubMed, Neurobiol Dis) - "Remarkably, long-term treatment with losartan-a brain-penetrant angiotensin II AT1 receptor antagonist-initiated in young, prehypertensive SHR blunted the age-dependent hypertension development and reversed the increase in neuronal labeling in both the PVN and RVLM...These findings demonstrate an age-dependent expansion of presympathetic neuronal connectivity from the hypothalamus and brainstem to the adrenal gland during the development of hypertension in SHR. Enhanced AT1 receptor activity may contribute to hypertension by increasing excitatory synaptic input and promoting the recruitment of additional presympathetic neurons in the brain."

Journal • Cardiovascular • Hypertension

Dual Thiol Drug-Induced Insulin Autoimmune Syndrome in a Non-Asian Patient Carrying HLA-DRB1*04:06: A Case Report and Literature Review. (PubMed, Clin Med Insights Case Rep) - "Management comprised immediate discontinuation of both captopril and ALA (captopril replaced with losartan) and dietary measures (frequent small low-carbohydrate meals). To our knowledge, this is the first reported case of IAS temporally associated with concurrent captopril and ALA exposure in a non-Asian carrier of HLA-DRB1*04:06. The case highlights the need to review both prescription drugs and supplements when investigating hyperinsulinemic hypoglycemia, that IAS can occur outside typical ethnic groups when permissive HLA alleles are present, and that prompt withdrawal of offending agents with conservative measures often leads to spontaneous remission."

Journal • Hypoglycemia • Immunology • Solid Tumor • HLA-DRB1

Comparative Effectiveness Of Losartan Versus Lisinopril On New-onset Heart Failure In Hypertension: A Propensity-matched Analysis [Poster no. 629] (HFSA 2026) - No abstract available

HEOR • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension